Abstract: A bionic vision sensor includes: a two-dimensional pixel array comprising a plurality of sensor pixels; a ROI module, wherein the ROI module is configured to obtain position information of at least one region of interest based on the two-dimensional pixel array; an image segmentation module, wherein the image segmentation module is configure to obtain at least one first region of the two-dimensional pixel array and at least one second region outside the first region according to the position information of region of interest; and a regional imaging control module, wherein the regional imaging control module is configured to generate a real-time image based on image data respectively obtained in the first region and the second region, and a pixel sampling rate of the first region is greater than a pixel sampling rate of the second region.

Abstract: A meniscal repair needle, comprising a needle rod, wherein the front section of the needle rod is warped in the shape of an arc and gradually reduces in size to form a needle tip as it extends forward, wherein the needle rod is configured to be a hollow structure, wherein a notch is formed in a front section of the needle rod, and wherein the notch expands inwards from the surface of the needle rod forming a hook portion, wherein an inner cavity of the needle rod extends into the notch, and wherein a hook tip of the hook portion faces the rear of the needle rod, wherein a rear section of the needle rod is connected with a hand-held portion.

Abstract: An NADH compound, and a formulation and use thereof, relating to the technical field of biomedicine and health care products. The NADH compound includes NADH or its physiologically acceptable salt and L-carnitine or its physiologically acceptable salt, and can be used as a weight loss product. The NADH compound has an increased effect in weight loss, and may achieve long-term drug administration of the product.

Abstract: An NADH compound, and a formulation and use thereof, relating to the technical field of biomedicine and health care products. The NADH compound includes NADH or its physiologically acceptable salt and L-carnitine or its physiologically acceptable salt, and can be used as a weight loss product. The NADH compound has an increased effect in weight loss, and may achieve long-term drug administration of the product.

Abstract: A method for purifying ?-nicotinamide mononucleotide (NMN) includes: sequentially microfiltrating and nanofiltrating a crude product solution containing NMN using membrane concentration devices to obtain a concentrated crude product solution; adjusting the concentrated crude product solution to pH 3-7 to obtain a loading solution, loading the loading solution onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and 100% ethanol as a mobile phase B, to obtain a purified sample solution; concentrating the purified sample solution by nanofiltration and freeze drying in a vacuum freeze drier to obtain a purified NMN.

Abstract: A method for purifying a salt of reduced form of ?-nicotinamide adenine dinucleotide (NADH) includes: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction, collecting a concentrate for use; adding an ion pair reagent to the concentrate, and purifying by gradient elution to obtain a purified filtrate using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; changing the cations in the purified filtrate into sodium ions to obtain a filtrate by using a cation exchange resin; and nanofiltrating the filtrate, and freeze drying in a vacuum freeze drier. The method results in an excellent purity and yield of a salt of NADH that meets requirements in industry.

Abstract: The present invention discloses a method for purifying reduced form of ?-nicotinamide adenine dinucleotide, comprising the steps of: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction, to collect a concentrate for use; then adding an ion pair reagent to the concentrate, and purifying by gradient elution using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; changing the cations in the purified filtrate into sodium ions by using a cation exchange resin; and nanofiltrating the filtrate obtained in Step c, and finally freeze drying it in a vacuum freeze drier. In the present invention, the reduced form of ?-nicotinamide adenine dinucleotide is purified by reverse phase high performance liquid chromatography and cation exchange, such that the reduced form of ?-nicotinamide adenine dinucleotide has a high purity and high yield, thus meeting the requirements in industry.

Abstract: The present invention discloses a method for purifying oxidized form of ?-nicotinamide adenine dinucleotide, comprising the steps of: sequentially microfiltrating and nanofiltrating a reaction solution obtained after an enzymatic reaction by using filteration membranes, to collect a concentrate for use; then adding an acid to the concentrated filtrate, to adjust the pH of the concentrate, and purifying by gradient elution using a reverse-phase chromatographic column as a stationary phase, a buffer solution as a phase A, and ethanol as a phase B; and concentrating the purified solution by nanofiltrating it with a filtration membrance, and then freeze drying it in a vacuum freeze drier. In the present invention, the oxidized form of ?-nicotinamide adenine dinucleotide is purified by reverse phase high performance liquid chromatography, such that the oxidized form of ?-nicotinamide adenine dinucleotide has a high purity and high yield, thus meeting the requirements in industry.

Abstract: The present invention discloses an oxidized form of ?-nicotinamide adenine dinucleotide phosphate and a method for purifying the same. The method comprises specifically the steps of: a. sequentially microfiltrating and nanofiltrating a pretreated coenzyme II solution with membrane concentration devices, to obtain a concentrated crude product solution; b. adjusting the obtained crude product solution to pH 2-4, loading it onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution, to obtain a purified sample solution; and c. nanofiltrating the purified sample solution with a membrane concentration device, and freeze drying it in a vacuum freeze drier, to obtain a purified coenzyme II. The coenzyme II prepared in the present invention has a high purity, a high yield, and thus a promising prospect in the market.

Abstract: The present invention discloses a method for purifying ?-nicotinamide mononucleotide, comprising the steps of: a. sequentially microfiltrating and nanofiltrating a pretreated ?-nicotinamide mononucleotide solution with membrane concentration devices, to collect a concentrated crude product solution; b. adjusting the obtained crude product solution to pH 3-7, loading it onto a preparative reverse phase high performance liquid chromatographic column, and purifying by gradient elution using an octadecylsilane-bonded silica gel as a stationary phase, a hydrochloric acid solution at pH 3-7 as a mobile phase A, and ethanol as a mobile phase B, to obtain a purified sample solution; and c. nanofiltrating the purified sample solution with a membrane concentration device, and freeze drying it in a vacuum freeze drier, to obtain purified ?-nicotinamide mononucleotide.